The when and wheres of CDC25 phosphatases

被引:337
作者
Boutros, R [1 ]
Dozier, C [1 ]
Ducommun, B [1 ]
机构
[1] Univ Toulouse 3, CNRS, UMR 5088, LBCMCP,IFR109, F-31062 Toulouse, France
关键词
D O I
10.1016/j.ceb.2006.02.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The CDC25 phosphatases are key regulators of normal cell division and the cell's response to DNA damage. Earlier studies suggested non-overlapping roles for each isoform during a specific cell cycle phase. However, recent data suggest that multiple CDC25 isoforms cooperate to regulate each cell cycle transition. For instance, although CDC25A was initially thought to exclusively regulate the G(1)-S transition, recent data demonstrate a significant role for CDC25A in the G(2)-M transition. Further evidence demonstrates that in addition to the ATM/ATR-CHK pathway, a p38-MAPKAP pathway is also involved in controlling CDC25 activity during G(2)/M checkpoint activation. Together with the fact that CDC25 overexpression is reported in many cancers, these data highlight the significance of developing specific CDC25 inhibitors for cancer therapy.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 71 条
  • [1] Cdc2-cyclin E complexes regulate the G1/S phase transition
    Aleem, E
    Kiyokawa, H
    Kaldis, P
    [J]. NATURE CELL BIOLOGY, 2005, 7 (08) : 831 - U93
  • [2] Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation
    Bahassi, ELM
    Hennigan, RF
    Myer, DL
    Stambrook, PJ
    [J]. ONCOGENE, 2004, 23 (15) : 2658 - 2663
  • [3] Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation
    Baldin, V
    Cans, C
    Knibiehler, M
    Ducommun, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (52) : 32731 - 32734
  • [4] Cdk2 knockout mice are viable
    Berthet, C
    Aleem, E
    Coppola, V
    Tessarollo, L
    Kaldis, P
    [J]. CURRENT BIOLOGY, 2003, 13 (20) : 1775 - 1785
  • [5] Blomberg I, 1999, MOL CELL BIOL, V19, P6183
  • [6] Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases
    Brezak, MC
    Quaranta, M
    Contour-Galcera, MO
    Lavergne, O
    Mondesert, O
    Auvray, P
    Kasprzyk, PG
    Prevost, GP
    Ducommun, B
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) : 1378 - 1387
  • [7] Novel synthetic inhibitor of CDC25 phosphatases:: BN82002
    Brezak, MC
    Quaranta, M
    Mondésert, O
    Galcera, MO
    Lavergne, O
    Alby, F
    Cazales, M
    Baldin, W
    Thurieau, C
    Harnett, J
    Lanco, C
    Kasprzyk, PG
    Prevost, GP
    Ducommun, B
    [J]. CANCER RESEARCH, 2004, 64 (09) : 3320 - 3325
  • [8] Dual phosphorylation controls Cdc25 phosphatases and mitotic entry
    Bulavin, DV
    Higashimoto, Y
    Demidenko, ZN
    Meek, S
    Graves, P
    Phillips, C
    Zhao, H
    Moody, SA
    Appella, E
    Piwnica-Worms, H
    Fornace, AJ
    [J]. NATURE CELL BIOLOGY, 2003, 5 (06) : 545 - 551
  • [9] Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase
    Bulavin, DV
    Higashimoto, Y
    Popoff, IJ
    Gaarde, WA
    Basrur, V
    Potapova, O
    Appella, E
    Fornace, AJ
    [J]. NATURE, 2001, 411 (6833) : 102 - 107
  • [10] Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
    Busino, L
    Donzelli, M
    Chiesa, M
    Guardavaccaro, D
    Ganoth, D
    Dorrello, NV
    Hershko, A
    Pagano, M
    Draetta, GF
    [J]. NATURE, 2003, 426 (6962) : 87 - 91